US regulator approves pill form of Wegovy weight-loss drugUS regulator approves pill form of Wegovy weight-loss drug
Wegovy becomes first pill of its kind to be approved, shifting weight-loss drugs beyond injections. Wegovy becomes first pill of its kind to be approved, shifting weight-loss drugs beyond injections.
US regulators approve Wegovy pill, first oral medication to treat obesityUS regulators approve Wegovy pill, first oral medication to treat obesity
Food and Drug Administration’s approval hands drugmaker Novo Nordisk an edge in the race to market an obesity pill US regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The US Food and Drug Administration’s approval handed drugmaker Novo Read More
FDA approves Wegovy pill for weight lossFDA approves Wegovy pill for weight loss
The Food and Drug Administration has approved a pill version of the weight-loss drug Wegovy. The Food and Drug Administration has approved a pill version of the weight-loss drug Wegovy.
Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist DiscontinuationGestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation
This cohort study examines gestational weight gain and pregnancy outcomes after glucagon-like peptide-1 (GLP-1) receptor agonist discontinuation. This cohort study examines gestational weight gain and pregnancy outcomes after glucagon-like peptide-1 (GLP-1) receptor agonist discontinuation.
Increasing Postpartum Use of GLP-1 Receptor AgonistsIncreasing Postpartum Use of GLP-1 Receptor Agonists
This study uses data from the Danish Medical Birth Register to examine postpartum use of glucagon-like peptide 1 receptor agonists. This study uses data from the Danish Medical Birth Register to examine postpartum use of glucagon-like peptide 1 receptor agonists.
Guiding Obstetric Care and Treatment Decisions for Women With Prior GLP-1 Receptor Agonist UseGuiding Obstetric Care and Treatment Decisions for Women With Prior GLP-1 Receptor Agonist Use
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as liraglutide and semaglutide, have revolutionized treatment of obesity. Obesity and obesity-related comorbidities increase the risks of adverse outcomes such as miscarriage, congenital malformations, preterm birth, gestational diabetes, and preeclampsia, which can have significant long-term consequences for mother and infant. By enabling women to begin pregnancy at a lower Read More
Adjuvant Chemotherapy for HR-Positive ERBB2- Negative Breast CancerAdjuvant Chemotherapy for HR-Positive ERBB2- Negative Breast Cancer
Oncology
Adjuvant Chemotherapy for HR-Positive, ERBB2 -Negative Breast CancerAdjuvant Chemotherapy for HR-Positive, ERBB2 -Negative Breast Cancer
This cohort study examines changes from 2010 to 2022 in use of adjuvant chemotherapy for early-stage hormone receptor–positive, ERBB2-negative breast cancer by age, genomic risk, and nodal involvement.
FDA approves Wegovy weight loss pill from Novo NordiskFDA approves Wegovy weight loss pill from Novo Nordisk
The Food and Drug Administration on Monday approved a pill version of Wegovy, Novo Nordisk’s blockbuster weight loss drug. The Food and Drug Administration on Monday approved a pill version of Wegovy, Novo Nordisk’s blockbuster weight loss drug.
FDA approves pill version of Novo Nordisk’s Wegovy, possibly widening accessFDA approves pill version of Novo Nordisk’s Wegovy, possibly widening access
The Food and Drug Administration on Monday approved the oral version of Novo Nordisk’s injectable weight loss drug Wegovy, making it the first GLP-1 pill to be cleared by regulators for obesity and possibly allowing many more Americans to access a highly effective treatment. The Wegovy pill, whose approval for weight loss was widely anticipated, Read More